Company
Headquarters: Irvine, CA, United States
Employees: 20
CEO: Dr. Bobak R. Azamian M.D.
$3.43 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $366.1 M |
| EBITDA | $-85,609,000 |
| Gross Profit TTM | $278.3 M |
| Profit Margin | -22.17% |
| Operating Margin | -12.24% |
| Quarterly Revenue Growth | 146.70% |
Tarsus Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TARS wb_incandescent